Kindred, TetraLogic stretch for $100M-plus as the biotech IPO market simmers

The once-vaunted biotech IPO scene has largely cooled over the past month, but Wall Street debutants TetraLogic ($TLOG) and Kindred Biosciences ($KIN) showed up in time to cash out. TetraLogic traded 7.2 million shares for $50 million--a fraction of the $103.5 million max the company craved back in October--and the biotech will put that cash toward its cancer drug development platform. Kindred cleared $53 million in an upsized offering, adding another almost 2 million more shares to its offering after scaling back its expected share price. That company's haul will help fund its animal drug programs for pain and severe itching. TetraLogic | Kindred

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.